High-performance liquid chromatographic determination of granisetron in human plasma

被引:24
作者
Pinguet, F
Bressolle, F
Martel, P
Salabert, D
Astre, C
机构
[1] FAC PHARM MONTPELLIER,LAB PHARMACOCINET,F-34060 MONTPELLIER 01,FRANCE
[2] CTR REG LUTTE CONTRE CANC,LAB ONCOPARMACOL,F-34094 MONTPELLIER,FRANCE
来源
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS | 1996年 / 675卷 / 01期
关键词
granisetron;
D O I
10.1016/0378-4347(95)00335-5
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
This paper describes a high-performance liquid chromatographic method (HPLC) with fluorometric detection for the analysis of granisetron in plasma. The detection is performed at 305 nm for excitation and 365 nm for emission. The method involves sample clean-up by liquid-liquid extraction. N-(1-Naphthyl) ethylenediamine dihydrochloride is used as internal standard. Toluene and phosphate buffer were added to 0.5 ml of plasma added to the internal standard. After extraction, the organic layer was separated and then evaporated to dryness. The residue was reconstituted in eluent mixture. An aliquot was injected onto the HPLC column, Spherisorb CN, equilibrated with an eluent mixture constituted by acetonitrile-phosphate buffer (pH 4.5) (15:85). The proposed technique is reproducible, selective, reliable, and sensitive. Linear detector responses were observed for the calibration curve standards in the range of 0.50 to 100 ng/ml. Extraction recovery from plasma proved to be more than 90%. Precision expressed as C.V. was in the range 2 to 8%. As low as 0.3 ng of granisetron per ml of plasma can be measured with good accuracy. The method has been validated, and stability tests under various conditions have been performed. Its sensitivity is adequate for pharmacokinetic studies.
引用
收藏
页码:99 / 105
页数:7
相关论文
共 17 条
[1]  
ALLEN A, 1990, BR PHARM SOC ABSTR, P619
[2]  
AUCLERC G, 1994, COMMUNICATION, V3, P1
[4]   PHARMACOKINETICS AND ANTI-EMETIC EFFICACY OF BRL43694, A NEW SELECTIVE 5HT-3 ANTAGONIST [J].
CASSIDY, J ;
RAINA, V ;
LEWIS, C ;
ADAMS, L ;
SOUKOP, M ;
RAPEPORT, WG ;
ZUSSMAN, BD ;
RANKIN, EM ;
KAYE, SB .
BRITISH JOURNAL OF CANCER, 1988, 58 (05) :651-653
[5]  
CLARKSON A, 1988, BR J CLIN PHARM, V25, P136
[6]   ON THE RECEIVING END PATIENT PERCEPTION OF THE SIDE-EFFECTS OF CANCER-CHEMOTHERAPY [J].
COATES, A ;
ABRAHAM, S ;
KAYE, SB ;
SOWERBUTTS, T ;
FREWIN, C ;
FOX, RM ;
TATTERSALL, MHN .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (02) :203-208
[7]   EVALUATION OF THE BIOEQUIVALENCE OF TABLET AND CAPSULE FORMULATIONS OF GRANISETRON IN PATIENTS UNDERGOING CYTOTOXIC CHEMOTHERAPY FOR MALIGNANT DISEASE [J].
CUPISSOL, D ;
BRESSOLLE, F ;
ADENIS, L ;
CARMICHAEL, J ;
BESSELL, E ;
ALLEN, A ;
WARGENAU, M ;
ROMAIN, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1993, 82 (12) :1281-1284
[8]  
CUPISSOL DR, 1990, EUR J CANCER, V26, pS23
[9]   SIMULTANEOUS DETERMINATION OF GRANISETRON AND 7-HYDROXYGRANISETRON IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION [J].
KUDOH, S ;
SATO, T ;
OKADA, H ;
KUMAKURA, H ;
NAKAMURA, H .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 660 (01) :205-210
[10]   COMPATIBILITY AND STABILITY OF GRANISETRON, DEXAMETHASONE, AND METHYLPREDNISOLONE IN INJECTABLE SOLUTIONS [J].
PINGUET, F ;
ROUANET, P ;
MARTEL, P ;
FABBRO, M ;
SALABERT, D ;
ASTRE, C .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (02) :267-268